Free Trial

Hikma Pharmaceuticals (HIK) Competitors

Hikma Pharmaceuticals logo
GBX 1,836 +15.00 (+0.82%)
As of 08/22/2025 11:50 AM Eastern

HIK vs. HCM, INDV, AMYT, AGY, APH, ANCR, VLG, STX, EAH, and DNL

Should you be buying Hikma Pharmaceuticals stock or one of its competitors? The main competitors of Hikma Pharmaceuticals include HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), Animalcare Group (ANCR), Venture Life Group (VLG), Shield Therapeutics (STX), ECO Animal Health Group (EAH), and Diurnal Group (DNL). These companies are all part of the "drug manufacturers - specialty & generic" industry.

Hikma Pharmaceuticals vs. Its Competitors

Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Hikma Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

In the previous week, Hikma Pharmaceuticals had 4 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Hikma Pharmaceuticals and 1 mentions for HUTCHMED. Hikma Pharmaceuticals' average media sentiment score of 1.12 beat HUTCHMED's score of -0.78 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hikma Pharmaceuticals
2 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
HUTCHMED
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative

Hikma Pharmaceuticals presently has a consensus target price of GBX 2,627.50, suggesting a potential upside of 43.11%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hikma Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
HUTCHMED
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.71% beat HUTCHMED's return on equity.

Company Net Margins Return on Equity Return on Assets
Hikma Pharmaceuticals9.45% 12.71% 9.40%
HUTCHMED -6.87%-5.71%-5.90%

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hikma Pharmaceuticals£3.74B1.36£353.21M£101.9118.02
HUTCHMED£771.01M3.37-£52.98M-£3.92-61.00

42.1% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 36.5% of HUTCHMED shares are held by institutional investors. 30.5% of Hikma Pharmaceuticals shares are held by insiders. Comparatively, 39.0% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Hikma Pharmaceuticals beats HUTCHMED on 13 of the 16 factors compared between the two stocks.

Get Hikma Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HIK vs. The Competition

MetricHikma PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£5.09B£2.27B£5.76B£3.22B
Dividend Yield2.65%2.92%4.40%5.04%
P/E Ratio18.024.3230.19164.70
Price / Sales1.36691.67474.98310,111.42
Price / Cash8.3410.3725.7827.93
Price / Book1.7911.949.425.91
Net Income£353.21M£20.70B£3.27B£5.89B
7 Day Performance1.91%1.29%2.05%49.44%
1 Month Performance-8.38%4.70%3.58%58.03%
1 Year Performance-8.84%5.11%30.09%141.20%

Hikma Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HIK
Hikma Pharmaceuticals
4.2043 of 5 stars
GBX 1,836
+0.8%
GBX 2,627.50
+43.1%
-8.8%£5.09B£3.74B18.029,100Positive News
Insider Trade
HCM
HUTCHMED
N/AGBX 245.89
+4.6%
N/A-9.1%£2.67B£771.01M-62.761,760News Coverage
High Trading Volume
INDV
Indivior
2.4447 of 5 stars
GBX 1,238
+1.6%
GBX 1,650
+33.3%
+33.8%£1.93B£1.40B-1,026.481,000Gap Up
High Trading Volume
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24M-4.33290Gap Down
AGY
Allergy Therapeutics
N/AGBX 8.75
+4.2%
N/A+87.1%£430.07M£72.18M-8.43612Gap Up
APH
Alliance Pharma
1.8899 of 5 stars
GBX 64.70
flat
GBX 6,250
+9,560.0%
N/A£350.32M£183.50M-10.4391,000
ANCR
Animalcare Group
N/AGBX 262
-1.1%
N/A-4.0%£179.63M£84.90M4.88220
VLG
Venture Life Group
N/AGBX 60.69
+4.6%
N/A+25.9%£77.33M£51.77M102.99165News Coverage
STX
Shield Therapeutics
N/AGBX 7
+7.7%
N/A+117.1%£69.08M£20.92M-1.8040,000News Coverage
Gap Up
High Trading Volume
EAH
ECO Animal Health Group
3.6829 of 5 stars
GBX 73.46
-0.1%
GBX 150
+104.2%
N/A£49.78M£89.44M47.49234
DNL
Diurnal Group
N/AN/AN/AN/A£46.33M£4.68M-3.2133

Related Companies and Tools


This page (LON:HIK) was last updated on 8/25/2025 by MarketBeat.com Staff
From Our Partners